• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

速效救心丸治疗新型冠状病毒肺炎急性感染期后综合征的潜在疗效：病例报告

A Potential Therapeutic Effect of Suxiao Jiuxin Pills in Treating Postacute Sequelae of COVID-19: Case Report.

作者信息

Sun Li, Li Nannan, Li Huilin, Zhang Qingshan, Bao Shuai, Li Xiaolu

机构信息

Department of Emergency Medicine, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, Shandong 250014, China.

出版信息

Case Rep Infect Dis. 2024 Nov 21;2024:4713552. doi: 10.1155/crdi/4713552. eCollection 2024.

DOI:10.1155/crdi/4713552
PMID:39619281
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11606693/
Abstract

Postacute Sequelae of COVID-19 Cardiovascular Syndrome (PASC-CVS) refers to a broad spectrum of cardiovascular symptoms that manifest four weeks or more after infection with COVID-19, which cannot be diagnosed as cardiovascular disease through standard examinations. Common symptoms include exercise intolerance and tachycardia, alongside persistent issues such as chest pain, chest tightness, and difficulty breathing. PASC-CVS significantly affects patients' quality of life; however, effective treatments for this condition are currently lacking. In this report, we present two cases of PASC-CVS patients who experienced well-controlled cardiovascular symptoms following treatment with Suxiao Jiuxin Pills. Our findings may offer a novel approach to the clinical management of PASC-CVS.

摘要

新型冠状病毒肺炎心血管综合征的急性后后遗症（PASC-CVS）是指新型冠状病毒肺炎感染四周或更长时间后出现的一系列广泛的心血管症状，通过标准检查无法诊断为心血管疾病。常见症状包括运动不耐受和心动过速，以及胸痛、胸闷和呼吸困难等持续性问题。PASC-CVS严重影响患者的生活质量；然而，目前缺乏针对这种情况的有效治疗方法。在本报告中，我们介绍了两例PASC-CVS患者，他们在服用速效救心丸治疗后心血管症状得到了良好控制。我们的发现可能为PASC-CVS的临床管理提供一种新方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a21/11606693/878205f02c22/CRIID2024-4713552.008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a21/11606693/6762c193d3e9/CRIID2024-4713552.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a21/11606693/9e3a7c1a35dc/CRIID2024-4713552.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a21/11606693/074ec03191bc/CRIID2024-4713552.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a21/11606693/f7ca2b288dda/CRIID2024-4713552.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a21/11606693/479d824ce065/CRIID2024-4713552.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a21/11606693/584d6fd2d642/CRIID2024-4713552.006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a21/11606693/9c5847f2a128/CRIID2024-4713552.007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a21/11606693/878205f02c22/CRIID2024-4713552.008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a21/11606693/6762c193d3e9/CRIID2024-4713552.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a21/11606693/9e3a7c1a35dc/CRIID2024-4713552.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a21/11606693/074ec03191bc/CRIID2024-4713552.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a21/11606693/f7ca2b288dda/CRIID2024-4713552.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a21/11606693/479d824ce065/CRIID2024-4713552.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a21/11606693/584d6fd2d642/CRIID2024-4713552.006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a21/11606693/9c5847f2a128/CRIID2024-4713552.007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a21/11606693/878205f02c22/CRIID2024-4713552.008.jpg

相似文献

1
A Potential Therapeutic Effect of Suxiao Jiuxin Pills in Treating Postacute Sequelae of COVID-19: Case Report.速效救心丸治疗新型冠状病毒肺炎急性感染期后综合征的潜在疗效：病例报告
Case Rep Infect Dis. 2024 Nov 21;2024:4713552. doi: 10.1155/crdi/4713552. eCollection 2024.
2
Efficacy of Suxiao Jiuxin Pill on Coronary Heart Disease: A Meta-Analysis of Randomized Controlled Trials.速效救心丸治疗冠心病的疗效：一项随机对照试验的Meta分析
Evid Based Complement Alternat Med. 2018 Mar 27;2018:9745804. doi: 10.1155/2018/9745804. eCollection 2018.
3
[Clinical characteristics and combined medication of Suxiao Jiuxin Pills in 16 856 elderly patients in real world study].[真实世界研究中16856例老年患者速效救心丸的临床特征及联合用药情况]
Zhongguo Zhong Yao Za Zhi. 2020 May;45(10):2335-2342. doi: 10.19540/j.cnki.cjcmm.20200302.501.
4
Chinese herbal medicine suxiao jiuxin wan for angina pectoris.治疗心绞痛的中药速效救心丸。
Cochrane Database Syst Rev. 2008 Jan 23;2008(1):CD004473. doi: 10.1002/14651858.CD004473.pub2.
5
Long COVID in pediatrics-epidemiology, diagnosis, and management.儿童长新冠 - 流行病学、诊断和管理。
Eur J Pediatr. 2024 Apr;183(4):1543-1553. doi: 10.1007/s00431-023-05360-y. Epub 2024 Jan 27.
6
Postacute Sequelae of COVID-19 and Adverse Psychiatric Outcomes: Protocol for an Etiology and Risk Systematic Review.新冠病毒病的急性后期后遗症与不良精神科结局：病因及风险系统评价方案
JMIRx Med. 2023 Mar 14;4:e43880. doi: 10.2196/43880.
7
Structural and functional impairments of skeletal muscle in patients with postacute sequelae of SARS-CoV-2 infection.新型冠状病毒感染后急性后遗症患者骨骼肌的结构和功能障碍。
J Appl Physiol (1985). 2023 Oct 1;135(4):902-917. doi: 10.1152/japplphysiol.00158.2023. Epub 2023 Sep 7.
8
Postacute Sequelae of COVID (PASC or Long COVID): An Evidenced-Based Approach.新冠后遗症（PASC 或长期新冠）：基于证据的方法。
Open Forum Infect Dis. 2024 Aug 27;11(9):ofae462. doi: 10.1093/ofid/ofae462. eCollection 2024 Sep.
9
Short-term and Long-term Rates of Postacute Sequelae of SARS-CoV-2 Infection: A Systematic Review.SARS-CoV-2 感染后急性后遗症的短期和长期发生率：系统评价。
JAMA Netw Open. 2021 Oct 1;4(10):e2128568. doi: 10.1001/jamanetworkopen.2021.28568.
10
Post-acute sequelae of SARS-CoV-2 cardiovascular symptoms are associated with trace-level cytokines that affect cardiomyocyte function.SARS-CoV-2 心血管症状的急性后期后遗症与影响心肌细胞功能的微量细胞因子有关。
Nat Microbiol. 2024 Dec;9(12):3135-3147. doi: 10.1038/s41564-024-01838-z. Epub 2024 Oct 30.

本文引用的文献

1
Evaluation of Outpatients in the Post-COVID-19 Period in Terms of Autonomic Dysfunction and Silent Ischemia.新冠疫情后门诊患者自主神经功能障碍和无症状性缺血情况评估
Cureus. 2023 Jun 11;15(6):e40256. doi: 10.7759/cureus.40256. eCollection 2023 Jun.
2
Suxiao Jiuxin Pill attenuates acute myocardial ischemia via regulation of coronary artery tone.速效救心丸通过调节冠状动脉张力减轻急性心肌缺血。
Front Pharmacol. 2023 May 10;14:1104243. doi: 10.3389/fphar.2023.1104243. eCollection 2023.
3
Suxiao Jiuxin Pill alleviates myocardial ischemia-reperfusion injury through the ALKBH5/GSK3β/mTOR pathway.
速效救心丸通过ALKBH5/GSK3β/mTOR通路减轻心肌缺血再灌注损伤。
Chin Med. 2023 Mar 23;18(1):31. doi: 10.1186/s13020-023-00736-6.
4
Post-COVID condition or "long COVID", return-to work, and occupational health research.新冠后状况或“长新冠”、重返工作岗位与职业健康研究
Scand J Work Environ Health. 2023 Apr 1;49(3):165-169. doi: 10.5271/sjweh.4088. Epub 2023 Mar 21.
5
Long COVID: 3 years in.新冠长期症状：三年过去了。
Lancet. 2023 Mar 11;401(10379):795. doi: 10.1016/S0140-6736(23)00493-2.
6
Long-COVID Syndrome and the Cardiovascular System: A Review of Neurocardiologic Effects on Multiple Systems.长新冠综合征与心血管系统：多系统神经心效应综述。
Curr Cardiol Rep. 2022 Nov;24(11):1711-1726. doi: 10.1007/s11886-022-01786-2. Epub 2022 Sep 30.
7
Serum proteomic analysis reveals the cardioprotective effects of Shexiang Baoxin Pill and Suxiao Jiuxin Pill in a rat model of acute myocardial infarction.血清蛋白质组学分析揭示了麝香保心丸和速效救心丸对急性心肌梗死大鼠模型的心脏保护作用。
J Ethnopharmacol. 2022 Jul 15;293:115279. doi: 10.1016/j.jep.2022.115279. Epub 2022 Apr 8.
8
2022 ACC Expert Consensus Decision Pathway on Cardiovascular Sequelae of COVID-19 in Adults: Myocarditis and Other Myocardial Involvement, Post-Acute Sequelae of SARS-CoV-2 Infection, and Return to Play: A Report of the American College of Cardiology Solution Set Oversight Committee.2022年美国心脏病学会关于成人新冠病毒感染心血管后遗症的专家共识决策路径：心肌炎及其他心肌受累、新冠病毒感染的急性后遗症以及恢复运动：美国心脏病学会解决方案集监督委员会报告
J Am Coll Cardiol. 2022 May 3;79(17):1717-1756. doi: 10.1016/j.jacc.2022.02.003. Epub 2022 Mar 16.
9
1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study.COVID-19 住院幸存者 1 年结局：一项纵向队列研究。
Lancet. 2021 Aug 28;398(10302):747-758. doi: 10.1016/S0140-6736(21)01755-4.
10
Cardiovascular disease in patients with COVID-19: evidence from cardiovascular pathology to treatment.COVID-19 患者的心血管疾病：从心血管病理学到治疗的证据。
Acta Biochim Biophys Sin (Shanghai). 2021 Mar 2;53(3):273-282. doi: 10.1093/abbs/gmaa176.